Clinical Trial Update: Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for povetacicept in primary membranous nephropathy, currently recruiting in Phase 2/3 to evaluate efficacy, safety, and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Membranous Nephropathy

Drugs mentioned

• Povetacicept (povetacicept)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Primary Membranous Nephropathy | Phase 2, Phase 3 | Status: RECRUITING